Retrophin, Inc. is a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for focal segmental glomerulosclerosis (FSGS), Duchenne Muscular Dystrophy and other catastrophic diseases.
The company's lead compound, RE-021, formerly known as DARA, is scheduled to begin enrollment in a Phase II clinical trial for FSGS In the near future. Additionally, the firm has entered a sponsored research agreement with St. Jude Children's Research Hospital to test its replacement therapy compounds for potential use in the treatment of pantothenate kinase-associated neurodegeneration (PKAN disease).
Retrophin's Series A financing was led by MSMB Capital and several current and former senior executives at global pharmaceutical and healthcare companies. – less–ZoomInfo